AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orlacchio, A.
Right arrow Articles by Simonetti, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlacchio, A.
Right arrow Articles by Simonetti, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

Evaluation of the Severity of Chronic Hepatitis C with 3-T1H-MR Spectroscopy

Antonio Orlacchio1, Francesca Bolacchi1, Marcello Cadioli2, Alberto Bergamini3, Valeria Cozzolino1, Mario Angelico4 and Giovanni Simonetti1

1 Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology, and Radiation Therapy, University Hospital Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy.
2 Philips Healthcare, Monza, Italy.
3 Department of Public Health and Cellular Biology, University Hospital Tor Vergata, Rome, Italy.
4 Hepatology Unit, Department of Internal Medicine, University Hospital Tor Vergata, Rome, Italy.


Figure 1
View larger version (47K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1 45-year-old healthy male volunteer. MR image shows voxel positioning.

 

Figure 2
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A Correlation between water content and disease severity. Graphs show no statistically significant correlation between water content (relative units) and degree of steatosis (A), histologic grade (B), or fibrosis stage (C).

 

Figure 3
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B Correlation between water content and disease severity. Graphs show no statistically significant correlation between water content (relative units) and degree of steatosis (A), histologic grade (B), or fibrosis stage (C).

 

Figure 4
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2C Correlation between water content and disease severity. Graphs show no statistically significant correlation between water content (relative units) and degree of steatosis (A), histologic grade (B), or fibrosis stage (C).

 

Figure 5
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3A Correlation between lipid level and disease severity. Graphs show elevation of lipid level (relative units) with severity of steatosis with clear separation between all steatosis grades (A), between histologic grade 0–1 versus histologic grade 2–3 hepatitis (B), and between stage of fibrosis 0–1 versus stage of fibrosis 2–3 hepatitis (C).

 

Figure 6
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3B Correlation between lipid level and disease severity. Graphs show elevation of lipid level (relative units) with severity of steatosis with clear separation between all steatosis grades (A), between histologic grade 0–1 versus histologic grade 2–3 hepatitis (B), and between stage of fibrosis 0–1 versus stage of fibrosis 2–3 hepatitis (C).

 

Figure 7
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3C Correlation between lipid level and disease severity. Graphs show elevation of lipid level (relative units) with severity of steatosis with clear separation between all steatosis grades (A), between histologic grade 0–1 versus histologic grade 2–3 hepatitis (B), and between stage of fibrosis 0–1 versus stage of fibrosis 2–3 hepatitis (C).

 

Figure 8
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4A Correlation between metabolite concentration and histologic grade. Graphs show elevation of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) with increasing grade. Separation between groups is clear.

 

Figure 9
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 4B Correlation between metabolite concentration and histologic grade. Graphs show elevation of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) with increasing grade. Separation between groups is clear.

 

Figure 10
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 5A Correlation between metabolite concentration and degree of steatosis. Graphs show ratios of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) at various steatosis grades. Clear separation between steatosis grade 0–1 and grade 2–3 is shown.

 

Figure 11
View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 5B Correlation between metabolite concentration and degree of steatosis. Graphs show ratios of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) at various steatosis grades. Clear separation between steatosis grade 0–1 and grade 2–3 is shown.

 

Figure 12
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 6A Correlation between metabolite concentration and stage of fibrosis. Graphs illustrate ratios of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) at various stages of fibrosis. Concentrations of choline-containing compounds and glutamine–glutamate complex showed no correlation with severity of fibrosis.

 

Figure 13
View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 6B Correlation between metabolite concentration and stage of fibrosis. Graphs illustrate ratios of concentration (relative units) of choline-containing compounds (CCC) (A) and glutamine–glutamate complex (Glx) (B) at various stages of fibrosis. Concentrations of choline-containing compounds and glutamine–glutamate complex showed no correlation with severity of fibrosis.

 

Figure 14
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7A 3-T 1H-MR spectra. Spectra of 48-year-old woman with hepatitis C virus (HCV) with grade 1 hepatitis and mild steatosis (A), 57-year-old woman with HCV with grade 2 hepatitis and moderate steatosis (B), and 52-year-old man with HCV with grade 3 hepatitis and severe steatosis (C) show progressive increase in choline-containing compound (CCC), glutamine–glutamate complex (Glx), and lipid (Lip) resonance.

 

Figure 15
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7B 3-T 1H-MR spectra. Spectra of 48-year-old woman with hepatitis C virus (HCV) with grade 1 hepatitis and mild steatosis (A), 57-year-old woman with HCV with grade 2 hepatitis and moderate steatosis (B), and 52-year-old man with HCV with grade 3 hepatitis and severe steatosis (C) show progressive increase in choline-containing compound (CCC), glutamine–glutamate complex (Glx), and lipid (Lip) resonance.

 

Figure 16
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7C 3-T 1H-MR spectra. Spectra of 48-year-old woman with hepatitis C virus (HCV) with grade 1 hepatitis and mild steatosis (A), 57-year-old woman with HCV with grade 2 hepatitis and moderate steatosis (B), and 52-year-old man with HCV with grade 3 hepatitis and severe steatosis (C) show progressive increase in choline-containing compound (CCC), glutamine–glutamate complex (Glx), and lipid (Lip) resonance.

 

Figure 17
View larger version (6K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7D 3-T 1H-MR spectra.D and E, Spectra of 52-year-old man with HCV infection and grade 0 hepatitis (D) and 47-year-old healthy male volunteer without steatosis (E).

 

Figure 18
View larger version (7K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 7E 3-T 1H-MR spectra.D and E, Spectra of 52-year-old man with HCV infection and grade 0 hepatitis (D) and 47-year-old healthy male volunteer without steatosis (E).

 

Figure 19
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 8A Scatterplots show distribution of complete set of cases by use of two first discriminant functions obtained for linear discriminant analysis: y-axis, value obtained with first discriminant function; x-axis, value obtained with second discriminant function. Plot shows complete set of cases for grading evaluation. Discriminant function 1 (score 1) has most discriminating power according to its eigenvalue of 9, 32 (F = 18.5; p < 0.001; Wilks {Lambda} = 0.096).

 

Figure 20
View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 8B Scatterplots show distribution of complete set of cases by use of two first discriminant functions obtained for linear discriminant analysis: y-axis, value obtained with first discriminant function; x-axis, value obtained with second discriminant function. Plot shows complete set of cases for steatosis evaluation. Discriminant function 1 (score 1) has most discriminating power (eigenvalue, 9, 26; F = 20.2; p < 0.001; Wilks {Lambda} = 0.085).

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Roentgen Ray Society.